One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Stereotaxis, Inc.
STXS · ASE · Healthcare · Medical Instruments & Supplies
Current price
$1.14
52-week range
$1.08 - $3.20
Market cap
$114.23M
Balance sheet
Healthy
-47.35x Concerning
Net cash $5.32M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
Stereotaxis, Inc.
Stereotaxis makes fancy robotic systems that help doctors perform heart procedures more precisely, and they also sell the disposable tools used with these machines. The money mainly comes from selling these robotic systems and the ongoing sales of the special disposable instruments (like catheters), which is important because it shows they have a steady stream of income beyond just the initial big sale of the robots. This business model, where they sell big machines and then also recurring sales of supplies, is key to their financial health.
How the company got here
Stereotaxis was founded in 1990 with a vision to revolutionize cardiac procedures using robotics. Early on, the company focused on developing magnetic navigation systems to give doctors more precise control during complex heart interventions. A key turning point was the development and FDA approval of their robotic magnetic navigation (RMN) systems, which allowed for minimally invasive catheter delivery within the heart. Over the years, Stereotaxis has continued to refine its technology, aiming to make these advanced robotic systems more accessible and easier to integrate into hospital labs.
What it actually does
Stereotaxis makes sophisticated robotic systems that help doctors perform delicate procedures inside the human body, particularly the heart. Think of it like a highly advanced remote control for tiny medical tools. These systems use magnets to guide catheters (thin, flexible tubes) with incredible precision through blood vessels to specific treatment areas. This allows physicians to perform complex interventions with less invasiveness than traditional methods, potentially leading to better patient outcomes and faster recovery times.
Robotic Magnetic Navigation (RMN) Systems
This is the core of Stereotaxis' business, representing the largest portion of its revenue. The company designs and sells robotic systems, like the Genesis RMN and GenesisX RMN, that use magnetic fields to steer catheters. Doctors use these systems during procedures like cardiac ablations, where they need to precisely navigate to specific spots in the heart to treat rhythm disorders. Hospitals and specialized cardiac centers are the primary customers, paying for the capital equipment and the advanced technology it represents.
Information and Imaging Systems
Beyond the robots themselves, Stereotaxis offers integrated information systems, such as Odyssey, which work alongside their RMN technology. These systems help manage, record, and share crucial data during procedures, providing real-time information to the physician. They also offer specialized X-ray systems that complement their robotic navigation. This segment is a smaller but important part of the business, enhancing the overall value proposition of their robotic solutions by improving workflow and data management in the interventional lab.
Disposables and Accessories
This segment includes the single-use items that doctors need to operate the robotic systems, such as specialized magnetic catheters (like the MAGiC catheter) and other devices. These are crucial for performing the actual procedures and are purchased by hospitals on an ongoing basis. While each disposable item might be relatively inexpensive, the recurring nature of their use makes this a consistent revenue stream for Stereotaxis, supporting the installed base of their larger robotic systems.
What management is betting on now
Stereotaxis' management is focused on making their advanced robotic technology more accessible and easier to adopt in hospitals. They are working on streamlining the installation process for their systems, as seen with the GenesisX RMN, to reduce the time and complexity required to set them up. The company is also emphasizing the integration of their robotic navigation with other diagnostic and therapeutic tools to offer a more comprehensive solution. The goal is to increase the adoption of robotic-assisted procedures, thereby expanding their market reach and revenue.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-4.34M
FY2024 Q4
$1.26M
FY2025 Q2
$-3.76M
FY2025 Q3
$-4.20M
FY2025 Q4
$-4.04M
FY2026 Q1
$-3.52M
FY2026 Q2
$-3.74M
Revenue
$7.67M
Net income
$-4.47M
Diluted EPS
-0.05
Operating cash flow
$-3.67M
Free cash flow
$-3.74M
Fetching…
Sources
Revenue
$6.29M
Net income
$-5.86M
Diluted EPS
-0.06
Operating cash flow
$-3.44M
Free cash flow
$-3.52M
Fetching…
Sources
Revenue
$8.64M
Net income
$-5.53M
Diluted EPS
-0.06
Operating cash flow
$-3.97M
Free cash flow
$-4.04M
Fetching…
Sources
Revenue
$7.46M
Net income
$-6.46M
Diluted EPS
-0.07
Operating cash flow
$-4.20M
Free cash flow
$-4.20M
Fetching…
Sources
Revenue
$8.80M
Net income
$-3.83M
Diluted EPS
-0.05
Operating cash flow
$-3.73M
Free cash flow
$-3.76M
Fetching…
Sources
Revenue
$7.47M
Net income
$-5.82M
Diluted EPS
-0.07
Operating cash flow
$-1.78M
Free cash flow
—
Fetching…
Sources
Revenue
$6.34M
Net income
$-7.51M
Diluted EPS
-0.09
Operating cash flow
$1.27M
Free cash flow
$1.26M
Fetching…
Sources
Revenue
$9.20M
Net income
$-6.19M
Diluted EPS
-0.08
Operating cash flow
$-4.33M
Free cash flow
$-4.34M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $1.14
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $5.3M - more cash than debt. Interest coverage -47.3x.
Net debt
$-5.32M
Interest coverage
-47.35x
Stereotaxis, Inc. is healthier than 0 of 1 peers on balance-sheet leverage.
Healthy
Worse cushion
Baseline
Better cushion
STXS
BASELINE
Stereotaxis, Inc.
Total debt $5.17M Interest coverage -47.35x This is the baseline the peer rows are being compared against.
What you should know
The case for and against STXS
0 Rewards
1 Risk
Rewards
Risks
-
Return on equity was -184.3% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-7.35x
P/B
9.12x
P/S
3.80x
EV/EBITDA
-6.32x
PEG ratio
1.31x
Profitability
How much profit each dollar creates
Gross margin
55.6%
Operating margin
-59.6%
Net margin
-74.2%
ROE
-184.3%
ROA
-25.4%
Health
Liquidity and balance-sheet strength
Debt / equity
0.30x
Current ratio
1.42x
Quick ratio
0.91x
Total debt
$5.17M
Total cash
$10.49M
Growth
How the business has been compounding
Revenue TTM
$30.07M
Revenue 5Y CAGR
-1.9%
EPS TTM
-0.24
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-15.29M
Free CF TTM
$-13.78M
FCF margin
-45.8%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—